Pizarro-Galleguillos Benjamin Matís, Kunert Liesa, Brüggemann Norbert, Prasuhn Jannik
Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
Department of Neurology, University Medical Center Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, Germany.
Antioxidants (Basel). 2023 Jul 12;12(7):1411. doi: 10.3390/antiox12071411.
There is a pressing need for disease-modifying therapies in patients suffering from neurodegenerative diseases, including Parkinson's disease (PD). However, these disorders face unique challenges in clinical trial designs to assess the neuroprotective properties of potential drug candidates. One of these challenges relates to the often unknown individual disease mechanisms that would, however, be relevant for targeted treatment strategies. Neuroinflammation and mitochondrial dysfunction are two proposed pathophysiological hallmarks and are considered to be highly interconnected in PD. Innovative neuroimaging methods can potentially help to gain deeper insights into one's predominant disease mechanisms, can facilitate patient stratification in clinical trials, and could potentially map treatment responses. This review aims to highlight the role of neuroinflammation and mitochondrial dysfunction in patients with PD (PwPD). We will specifically introduce different neuroimaging modalities, their respective technical hurdles and challenges, and their implementation into clinical practice. We will gather preliminary evidence for their potential use in PD research and discuss opportunities for future clinical trials.
对于患有神经退行性疾病（包括帕金森病（PD））的患者而言，迫切需要能够改变疾病进程的疗法。然而，在评估潜在候选药物的神经保护特性的临床试验设计中，这些疾病面临着独特的挑战。其中一个挑战涉及通常未知的个体疾病机制，而这些机制对于靶向治疗策略而言却是相关的。神经炎症和线粒体功能障碍是两种被提出的病理生理特征，并且在帕金森病中被认为是高度相互关联的。创新的神经成像方法有可能有助于更深入地了解个体主要的疾病机制，能够促进临床试验中的患者分层，并且有可能描绘治疗反应。本综述旨在强调神经炎症和线粒体功能障碍在帕金森病患者（PwPD）中的作用。我们将特别介绍不同的神经成像模式、它们各自的技术障碍和挑战，以及它们在临床实践中的应用。我们将收集它们在帕金森病研究中潜在用途的初步证据，并讨论未来临床试验的机会。
